POTASSIUM HYDROGEN DL-ASPARTATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C4H5NO4.K.H
Molecular Weight	171.193
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of POTASSIUM HYDROGEN DL-ASPARTATE

Structure Search

SMILES

[H+].[K+].NC(CC([O-])=O)C([O-])=O

InChI

InChIKey=TXXVQZSTAVIHFD-UHFFFAOYSA-M

InChI=1S/C4H7NO4.K/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25954929 | http://www.sigmaaldrich.com/catalog/product/sigma/a2025?lang=en®ion=RU&cm_sp=Insite-_-recent_fixed-_-recent5-1 | https://www.ncbi.nlm.nih.gov/pubmed/19716665

Potassium hydrogen DL-aspartate has being shown to inhibit cell damage and apoptosis induced by ouabain and H2O2. Principal neurotransmitter for fast synaptic excitation. DL-Aspartic acid (DL-Asp) is a racemic mixture of the proteinogenic amino acid L-aspartate and the non-proteinogenic amino acid D-aspartate. DL-Aspartic acid is used in studies on factors and conditions that enhance semen and sperm quality. DL-Aspartic acid is used to develop and assess amino acid racemic resolution and racemic interconversion technologies. Principal neurotransmitter for fast synaptic excitation. It has being shown that DL-Aspartic acid (DL-Asp) administration improves sperm quality in bucks and the high D-Asp content in seminal plasma suggests a primary role for this D-amino acid in regulatory mechanisms of reproductive activity.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Microsporum gypseum 2 Target ID: CHEMBL612945 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6540570	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Male infertility 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19716665	Primary	Preclinical	Unknown Approved Use Unknown
Cochlear disease 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12764776	Secondary	Preclinical	Unknown Approved Use Unknown
Convulsions 72 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14413228 https://www.ncbi.nlm.nih.gov/pubmed/13843280	Primary	Preclinical	Unknown Approved Use Unknown
Hyperammonemia 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13609089	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Potassium aspartate inhibits SH-SY5Y cell damage and apoptosis induced by ouabain and H2O2.	2015-08	25954929
X-ray absorption near-edge structure (XANES) spectroscopy study of the interaction of silver ions with Staphylococcus aureus, Listeria monocytogenes, and Escherichia coli.	2013-10	23934494
[Protective effect of potassium and magnesium salts of DL-aspartic acid against convulsions caused by isoniazid and ammonium chloride in the rat].	1959-11-03	14413228
[Effect of potassium and magnesium salts of dl-aspartic acid on total plasma CO2 in induced hypercapnea in dogs].	1958	13619185

Patents

Sample Use Guides

In Vivo Use Guide

Rabbit bucks: The treated group was fed with a concentrate containing DL-Aspartic acid (DL-Asp) which assured a daily administration of 1.3g dl-Asp/head

Route of Administration: Oral

In Vitro Use Guide

The cell survival rates following 48 h incubation in the Potassium hydrogen DL-aspartate (K-asp) (15 mM) and K-asp (25 mM) groups were higher compared with the KCl and MK801 groups. Nissl staining demonstrated that the severity of cell injury in the KCl and K-asp (25 mM) groups were alleviated. In the DAPI staining and transmission electron microscopy analyses, KCl and K-asp (25 mM) reduced the rate of ouabain-induced apoptosis. Flow cytometry revealed that K-asp (25 mM) reduced H2O2 -induced apoptosis. These results demonstrated that K-asp (25 mM) inhibited the ouabain and H2O2-induced SH-SY5Y cell damage and apoptosis, possibly by supplementing levels of intracellular K(+).

Name

Type

Language

POTASSIUM HYDROGEN DL-ASPARTATE

Preferred Name

English

Code System Code Type Description

EPA CompTox

DTXSID401021780